Oral squamous cell carcinoma in dogs: treatment, prognosis and clinical trials

Dogs · USA & Canada

Understanding oral squamous cell carcinoma

Oral squamous cell carcinoma is a cancer of the lining of the mouth that tends to grow into nearby tissue and bone. In dogs, some tumors can be controlled well if they are found in a surgically favorable location, while others are difficult because of size or anatomy. Exact site, bone invasion and stage matter greatly.

What does the prognosis look like?

Canine oral squamous cell carcinoma is often primarily a local-control problem, and some dogs with tumors that can be completely removed can do well for a long time. Tumor site, size, bone invasion, lymph-node involvement and the ability to obtain clean local control are the major factors that shape prognosis.

What matters next

Define exactly where the tumor starts, how large it is and whether it has invaded jaw bone or nearby structures. Those findings often determine whether surgery can realistically remove it and whether radiation or another local treatment should be considered. Pain, bleeding and difficulty eating should be addressed at the same time.

Where are you now?

The tumor is still present and surgery is being considered

Define local extent and bone involvement before a major oral surgery. The useful question is whether complete removal is realistic with acceptable function, not simply whether the visible mass can be cut out.

The tumor was removed with incomplete margins

Review measured margins and whether bone was involved. A wider resection or radiation may offer better local control than waiting for visible regrowth, depending on anatomy and expected morbidity.

Complete surgery is not feasible

Radiation or another local treatment may still provide control or palliation. Eating, pain, bleeding, and oral function should be part of the treatment decision rather than treated as separate problems.

Nodes or distant metastases are present

Confirm whether spread is regional or distant and what it actually changes. Local treatment may still be useful for the mouth while systemic options are considered separately.

If you are waiting for oncology

Local anatomy drives the next decision. Obtain biopsy confirmation and imaging of bone and deep tissue before a major oral surgery when possible. Worsening pain, bleeding, inability to eat or airway problems should accelerate evaluation rather than wait for a routine slot.

Questions to ask your oncologist

How much bone or deep tissue is involved, and is complete surgery realistic?
Do the regional lymph nodes need sampling?
If surgery cannot achieve useful margins, what local treatment gives the best chance of control or comfort?

How the diagnosis may appear in the record

The report should identify the exact oral site and whether jaw bone is invaded. Margin measurements and lymph-node results matter after surgery. Tonsillar squamous cell carcinoma should be identified separately because it generally carries greater metastatic concern than many non-tonsillar oral tumors.

Changes to watch for at home

Eating more slowly, dropping food, drooling, bleeding, mouth odor, weight loss, facial swelling, or difficulty opening the mouth can reflect local progression. Inability to eat or drink, uncontrolled bleeding, or breathing difficulty needs prompt care. Nutrition and pain control should be addressed early.

How it is usually treated

Surgery gives the best chance of durable control when the tumor can be completely removed without unacceptable loss of function. Radiation can be used when surgery is incomplete, not feasible or intended only for palliation. Systemic treatment has a more limited role and is chosen according to site, stage and tumor behavior.

What can affect treatment choices

Exact mouth location, tumor size, bone invasion, lymph-node involvement and whether local treatment can remove or control the tumor without unacceptable loss of function shape the plan.

Tests that may matter

Biopsy confirms the tumor type, and local imaging helps show how much jaw bone or nearby soft tissue is involved before major surgery or radiation. Regional lymph-node sampling and chest staging are considered when they would change treatment.

Treatment options available now

6 options currently in our catalog.

Check eligibility

Trametinib for canine oral squamous cell carcinoma

Cornell University · USA

Location

Cornell University Hospital for Animals, 930 Campus Rd, Ithaca, NY 14853

Study details

Current / recruiting

What is being offered: Dogs seen by Cornell University Hospital for Animals with diagnosed oral SCC are eligible for prescreen. Daily oral trametinib with scheduled follow-up through day 126. Cornell's live Clinical Trials roster and live contact form both currently offer this study.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required

Costs / coverage: 🟢 Fully funded. All study visits, procedures and trametinib are free; dogs completing the study also receive a $1,000 credit toward standard-of-care SCC medical expenses.

Contact: PI Santiago Peralta, DVM, AVDC, FF-AVDC-OMFS; Cornell Dentistry/Oral Surgery or Oncology/Clinical Trials Coordinator, 607-253-3060; vet-research@cornell.edu

Official study / enrollment information →

Combinatorial PDL1-IRDye800 imaging to guide surgery for canine oral cancer

UC Davis Veterinary Center for Clinical Trials · USA

Location

UC Davis Veterinary Medical Teaching Hospital, 1 Garrod Dr, Davis, CA 95616

Study details

Active - Recruiting

What is being offered: Protocol VCCT-26-008 enrolls dogs over one year old with confirmed oral SCC or oral malignant melanoma that are healthy enough for anesthesia and repeated visits. Anti-PDL1-IRDye800 is administered IV twice before near-infrared imaging at 8, 24 and 48 hours and repeat biopsy or curative-intent surgery. Recruitment period: 2026-06-30 through 2028-06-29.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Anesthesia eligible; Min age years exclusive: 1

Costs / coverage: 🟡 Partially funded. The study covers the pre-operative biopsy and additional hospitalization time and provides a $1,500 incentive toward therapy; owners pay screening, oral-tumor workup and treatment costs beyond that incentive.

Contact: UC Davis VCCT — vcct@ucdavis.edu; 530-754-1954

Official study / enrollment information →

Evaluation of TLR agonist Z-007 in dogs with cancer

Cummings School of Veterinary Medicine, Tufts University · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Compassionate-Use Protocol for Advanced Non-Resectable Tumors

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Single-fraction SABR for progressive canine lung metastases

Tufts Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →

Cathepsin-activated near-infrared imaging during surgery for canine oral squamous cell carcinoma

University of Pennsylvania School of Veterinary Medicine · USA

Location

Penn Vet Ryan Veterinary Hospital, 3900 Spruce St, Philadelphia, PA 19104

Study details

Recruiting — posted October 21, 2026

What is being offered: Intravenous cathepsin-activated near-infrared imaging agent and intraoperative imaging during surgical excision

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned surgery; Previously untreated

May not qualify if: Prior surgery; Prior radiation; Prior chemo

Costs / coverage: 🟡 Partially funded. The study pays $3,000 toward the cost of surgery; Penn Vet does not state that the remaining surgical, screening, staging or follow-up costs are covered.

Contact: Penn Vet VCIC — 215-573-0302; vcic@vet.upenn.edu

Official study / enrollment information →